Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms.

Milena GusellaFelice PasiniDonatella CarusoCarmen BarileYasmina ModenaAnna Paola FracconLaura BertolasoDaniela MenonGiorgio CrepaldiAntonio BononiRoberto SpezzanoGiorgia Anna TelatinGiuseppe CoronaRoberto Padrini

Published in: Cancer chemotherapy and pharmacology (2018)

Neither pharmacokinetic nor pharmacogenetic monitoring seem useful to predict OS. On the other hand, high VNR and dVNR blood levels were associated with severe toxicity.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
multidrug resistant
oxidative stress
early onset
phase ii study
clinical trial
radiation therapy
open label
double blind